Report : Middle East & Africa Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others) 

At 8.3% CAGR, the Middle East & Africa pharma ADMET testing market is speculated to be worth US$ 437.71 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa pharma ADMET testing market was valued at US$ 270.94 million in 2022 and is expected to reach US$ 437.71 million by 2028, registering an annual growth rate of 8.3% from 2022 to 2028. The advent of high-throughput screening and high rate of late-stage drug failure are the critical factors attributed to the market expansion.

Over the last decade, the pharmaceutical industry has witnessed many transformational trends and innovations that have the potential to rapidly improve medicines available on market. In the last 10 years, the influence of AI and Big Data analytics on disease diagnosis and treatment, and a shift toward preventing life-threatening conditions rather than curing them have led to the evolution of healthcare. With the continuous evolution of science and technology, exciting developments in the field of high throughput ADME (HT-ADME) research are highly anticipated in the next decade. The emerging fields of ADME sciences will find their way into ADME screening studies from the perspective of the assay repertoire. The novel, physiologically appropriate in vitro micro physiological systems (MPS), such as 3D tissue cultures and organ(s)-on-a-chip, are likely to make their way in the improvement efforts for in vitro in vivo translation (IVIVT). The use of endogenous probes (basic biomarkers) for in vivo transporter drug-drug interaction (DDI) investigations is coming up as another trend in ADME testing, as this approach can lower pill burden and help obtain transporter DDI data from a standard phase I trial. The HT-ADME screening of innovative drug delivery systems is yet another example. The field is prepared to undertake early ADME screening of novel modalities, such as protein degraders, antisense oligonucleotides (ASOs), antibody-drug conjugates (ADCs), and biologics, in addition to small molecules and peptides. Although the ADME studies for these modalities are still in the developing stage, an increasing number of HT-ADME format assays are anticipated to go online to support ongoing scientific research. With the long history of HT-ADME operation in many companies and the resulting wealth of ADME data that can be “mined”, the development of in silico models to predict ADME properties has long been acknowledged as the obvious next step for HT-ADME screening. The HT-ADME dataset of any big pharmaceutical company could include test findings from numerous compounds, in contrast to many ADME prediction models described in the literature that employ a training set of a smaller number of compounds. Due to their size, these datasets can prove to be the best training sets for model building. ADME features have long been studied using computational chemistry methods designed to create quantitative structure-activity relationship (QSAR) models. Models for clearance, permeability, and DDI potentials have recently been developed using various machine learning (ML) techniques. Hit triaging from lead discovery screens and the design-make-test cycles of lead optimization in drug discovery, among others, can be employed to obtain predictive ADME models due to the recent rapid developments in ML methodologies and the large size of the HT-ADME datasets available for use as training sets. These top trends will transform the pharmaceutical industry and can have short-term and long-term benefits on the ADMET testing market.

On the contrary, high cost of ADME testing studies hurdles the growth of Middle East & Africa pharma ADMET testing market.

Based on testing type, the Middle East & Africa pharma ADMET testing market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment held 52.7% market share in 2022, amassing US$ 142.75 million. It is projected to garner US$ 229.60 million by 2028 to expand at 8.2% CAGR during 2022–2028.

Based on technology, the Middle East & Africa pharma ADMET testing market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment held 43.1% market share in 2022, amassing US$ 116.73 million. It is projected to garner US$ 189.92 million by 2028 to expand at 8.5% CAGR during 2022–2028.

By the application, the Middle East & Africa pharma ADMET testing market is fragmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. With 70.8% share of the domain, the systemic toxicity segment dominated the market in 2022. It accrued US$ 191.75 million in 2022 and is estimated to generate US$ 311.76 million by 2028 to grow at a CAGR of 8.4% over the forecast period.

Based on country, the Middle East & Africa pharma ADMET testing market is categorized into South Africa, Saudi Arabia, the UAE, and the rest of Middle East & Africa. Our regional analysis states that South Africa captured 35.9% market share in 2022. It was assessed at US$ 97.29 million in 2022 and is likely to hit US$ 155.28 million by 2028, exhibiting a CAGR of 8.1% during the forecast period.

Key players dominating the Middle East & Africa pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; MERCK KGaA; Promega Corporation; and Wuxi AppTec among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id:

Download Free PDF Brochure